 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Mar 21 Calls Today's Calls |
| Call Details | |||
| Q4 and 2012 StemCells, Inc. Earnings Conference Call Scheduled to start Thu, Mar 21, 2013, 4:30 pm Eastern -- this event is ongoing now--
| |||
| About StemCells Inc (NasdaqCM:STEM) | |||
| StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of stem cell therapeutics and related technologies. It develops cell-based therapeutics for the central nervous system and liver. The company’s lead product candidate, HuCNS-SC cells have completed a Phase I clinical trial for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis, a neurodegenerative disease that affects infants and young children. HuCNS-SC cells are also in Phase I clinical trial for the treatment of Pelizeaus-Merzbacher disease, a fatal myelination disorder in the brain. In addition, it involves in preclinical development with its human liver engrafting cells (hLEC) to evaluate hLEC as a potential cellular therapy for a range of liver diseases. Further, the company is developing and commercializing applications of its technologies to enable stem cell-based research to academic and industrial laboratories. It markets a range of proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2B27, NDiff 2 and 27 supplements, HEScGRO, and ESGRO Complete proprietary media. StemCells, Inc. has exclusive rights to approximately 50 issued or allowed U.S. patents, and 200 granted or allowed non-U.S. patents. The company was founded in 1988 and is based in Palo Alto, California. | |||
More Info: | |||
